Literature DB >> 18763221

Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures.

M Jäger1, T Messer, G Laux, H Pfeiffer, D Naber, L G Schmidt, W Gaebel, J Klosterkötter, I Heuser, W Maier, M R Lemke, E Rüther, G Buchkremer, M Gastpar, M Riedel, R Bottlender, A Strauss, H-J Möller.   

Abstract

INTRODUCTION: Standardized consensus criteria for remission in schizophrenia were recently proposed. As yet, the validity of these criteria and their comparability with previously used outcome measures are unclear.
METHODS: The symptom-severity component of the proposed remission criteria was applied to 288 inpatients who fulfilled the ICD-10 criteria for schizophrenia. Global functioning and psychopathological symptoms were assessed using GAF, PANSS, SANS, HAM-D and CDSS.
RESULTS: When patients with symptom remission at discharge from hospitalization (n=158, 54.9%) were compared to those without symptom remission, significant differences were found with respect to the global functioning (GAF) and all observed psychopathological symptom dimensions. The percentage agreement with previously used outcome measures ranged between 52.6 and 80.0%, the kappa values between 0.120 and 0.594. A moderate accordance (kappa value: 0.495) was found with a Clinical Global Impression (CGI) severity score of three or less. DISCUSSION: The results indicate a high descriptive validity of the symptom-severity component of the proposed remission definition. However, the new criteria differ partially from previously used outcome measures. This aspect should be considered in the interpretation of clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18763221     DOI: 10.1055/s-2008-1078745

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

1.  [Polypharmacy in schizophrenia].

Authors:  M Zink; S Englisch; A Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2011-07       Impact factor: 1.214

2.  Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

3.  Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment?

Authors:  Zhang Cheng; Yanbo Yuan; Xue Han; Lei Yang; Xin Zeng; Fude Yang; Zheng Lu; Chuanyue Wang; Hong Deng; Jingping Zhao; Xin Yu
Journal:  Front Psychiatry       Date:  2020-06-19       Impact factor: 4.157

4.  Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study.

Authors:  Bernardo Carpiniello; Federica Pinna; Massimo Tusconi; Enrico Zaccheddu; Francesca Fatteri
Journal:  Schizophr Res Treatment       Date:  2012-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.